Homeopathy 2005; 94(01): 26-32
DOI: 10.1016/j.homp.2004.10.003
Original Paper
Copyright ©The Faculty of Homeopathy 2004

Histopathological and immunophenotyping studies on normal and sarcoma 180-bearing mice treated with a complex homeopathic medication

D.Y.O. Sato
1  Universidade do Vale do Itajaí
,
R. Wal
2  Hospital de Clínicas da Universidade Federal do Paraná
,
C.C. de Oliveira
3  Departamento de Biologia Celular do Setor de Ciências Biológicas da Universidade Federal do Paraná, Centro Politécnico, Jardim das Américas, Curitiba, Paraná, Brazil
,
R.I.I. Cattaneo
2  Hospital de Clínicas da Universidade Federal do Paraná
,
M. Malvezzi
2  Hospital de Clínicas da Universidade Federal do Paraná
,
J. Gabardo
4  Departamento de Genética da Universidade Federal do Paraná, Brazil
,
D. de F Buchi
3  Departamento de Biologia Celular do Setor de Ciências Biológicas da Universidade Federal do Paraná, Centro Politécnico, Jardim das Américas, Curitiba, Paraná, Brazil
› Author Affiliations
Further Information

Publication History

Received 29 June 2004
revised27 September 2004

accepted25 October 2004

Publication Date:
13 December 2017 (online)

Abstract

Canova is a homeopathic complex medicine, used as an immune modulator. We studied its effects in normal and sarcoma 180-bearing mice. Three control groups were also evaluated. The mice were examined at daily intervals and the tumours observed histologically. Peripheral blood was analysed by flow cytometry.

A delay in the development, and a reduction in size of the tumours, and increased infiltration by lymphoid cells, granulation tissue, and fibrosis surrounding the tumour were observed with active treatment compared to control. All animals from the treated group survived, 30% of control groups died. In 30% of treated animals, a total regression of the tumour was confirmed using light microscopy, no regression was found in the control groups. Treatment with Canova increased total numbers of leukocytes and lymphocytes. Among lymphocytes, TCD4, increased in normal-treated group and B and NK cells in S180-treated groups. The results reflect enhanced immune response of the host after treatment with Canova.